Bristol-Myers Interferon-Free Combo Cured Hepatitis C Patients

StephenW

http://www.bloomberg.com/news/2011-04-02/bristol-myers-interferon-free-combo-cured-hepatitis-c-patients.html
Bristol-Myers Interferon-Free Combo Cured Hepatitis C Patients                                                          By Naomi Kresge -               Apr 3, 2011 2:30 AM ET                    
                                            

•                     
  

• [url=]inSha[/url]

  l
  

                                  Bristol-Myers Squibb Co. (BMY)’s cocktailof two experimental drugs cured four hepatitis C patients in thefirst success for a therapy that excludes often-toxic existingdrugs.
The combination had a higher rate of success when pairedwith the current standard treatment in the 21-person trial,curing nine of 10 patients, researchers said today at the Berlinmeeting of the European Association for the Study of the Liver.The study points to the next generation of drugs for the evasivevirus, said Mark Thursz, a professor of hepatology at ImperialCollege London and vice-secretary of EASL.
Bristol-Myers, based in New York, is among about a dozencompanies trying to make better drug combinations that eitherinclude interferon, a decades-old shot that causes flu-likesymptoms and only works in half of patients, or that replaceinterferon entirely. At stake is leadership in a market thatJefferies International Ltd. estimates may total $15 billion ayear by 2019.
“This is perhaps one of the most exciting developmentsthis year,” Thursz said in an interview. “For some patientswho are not going to tolerate interferon, this is the light atthe end of the tunnel.”
Bristol-Myers plans to begin the last trials required forregulatory approval this year, Douglas Manion, the drugmaker’shead of neuroscience and virology research, said in aninterview.
Toughest-to-Treat Today’s trial studied the Bristol-Myers drugs, BMS-790052and BMS-650032, in patients for whom existing therapies hadn’tbeen successful, “the toughest-to-treat population,” Manionsaid.
Ten patients got the two drugs together with interferon andgeneric ribavirin. All showed no sign of the virus 12 weeksafter the treatment was over. One patient had signs of virus at24 weeks and was again virus-free in another follow-up test 35days later.
Of 11 patients who took the Bristol-Myers combinationalone, five had cleared the virus from their bodies at the endof treatment. Four remained virus-free after 24 weeks.
Patients may start treatment earlier if they aren’t facedwith the toxic side effects of traditional hepatitis C drugs,said Howard Liang, a Boston-based analyst for Leerink Swann &Co., in an interview.
“If you have an interferon-free regimen, the marketexpands fairly dramatically,” Liang said.
Side Effects Side effects of the existing interferon regimen are oftensevere enough to force patients to take time off work, saidCharles Gore, president of the Geneva-based patient advocacygroup World Hepatitis Alliance.
Roche Holding AG (ROG) of Basel, Switzerland, sells a version ofinterferon under the brand name Pegasys, while Merck & Co. ofWhitehouse Station, New Jersey markets a form called PegIntron.
Merck, Vertex Pharmaceuticals Inc. (VRTX) and Johnson & Johnsonare expected to bring the first new hepatitis C drugs in adecade to the market this year. About 90 percent of patients whotook Johnson & Johnson (JNJ) and Vertex’s telaprevir were cured,Cambridge, Massachusetts-based Vertex said in two studies lastyear. Patients given Merck’s boceprevir showed similarly highcure rates in studies last year.
The Vertex and Merck trials included people who hadn’t yetbeen treated, an easier-to-cure group than those in today’ssmaller study. By comparison, about 30 percent of those whohadn’t responded to previous treatment were cured after tryingtelaprevir plus standard therapy, researchers said.
Seeking Partners Merck is seeking partnerships to gain its own hepatitis Cdrug combinations, Patrick Bergstedt, general manager of theinfectious diseases franchise, said in an interview.
“We’re behind the others,” Bergstedt said. “We need topartner to fill the gap.”
Bristol-Myers expects an “element of consolidation” ascompanies use acquisitions, partnerships and research anddevelopment collaborations to gain their own hepatitis C drugcombinations, Manion said. After signing a development deal withPrinceton, New Jersey-based Pharmasset Inc. (VRUS) in January, Bristol-Myers is “talking to pretty much every company out there,” hesaid.
“This is like trying to redesign a car as you’re rollingdown the road at 100 miles per hour, because the data are comingso fast,” he said. “What an exciting time.”
To contact the reporter on this story:Naomi Kresge in Frankfurt at [email protected]
To contact the editor responsible for this storyhil Serafino at [email protected]
                                      
        

•                     
  
  

        Last update: 11:46 AM ET, Apr 2   
                        
        

我随心动

非干扰药物治愈的病例，不错。

limi2011321

施贵宝干扰素无组合固化肝炎纳奥米克雷奇C的病人 - 2011年4月3日上午02:30东部
                                             
•

•[网址=] inSha [/网址]

升

                                  施贵宝公司（BMY牛）的cocktailof二治愈四肝炎的治疗thefirst排除经常无毒existingdrugs C的病人成功的实验性药物。
这种组合有更高的成功率时pairedwith目前标准治疗的21人的审判中，10例治愈九，研究人员表示，在欧洲协会Berlinmeeting的Liver.The的研究指出未来的研究今日为evasivevirus药物的产生，马克说Thursz，在ImperialCollege肝脏病学教授，英国伦敦和副主席的欧洲肝病学会的秘书。
施贵宝，总部设在纽约，是在大约一dozencompanies努力做出更好的药物组合，eitherinclude干扰素，数十年的拍摄，导致流感likesymptoms和一半的患者只作品，或replaceinterferon完全。在股权是在市场thatJefferies领导国际有限公司由2019年的估计可能达到150亿美元ayear。
“这也许是最令人兴奋的developmentsthis元年”Thursz在采访中说。 “对于一些patientswho不会容忍干扰素，这是光隧道结束了进去。”
施贵宝计划开始需要forregulatory批准今年的最后审判，道格拉斯马尼恩，对神经科学和病毒学研究drugmaker'shead说，在aninterview。
最难性治疗今天的试验研究的布里斯托尔迈尔斯药物，拜耳- 790052and的BMS - 650032的患者，对他们来说，现有疗法hadn'tbeen成功，“最艰难到治疗人群，”Manionsaid。
十位病人得到了两种药物一起使用干扰素andgeneric利巴韦林。所有没有表现出病毒治疗12 weeksafter结束的迹象。一位病人的病毒at24周的迹象，并再次在另一项跟进测试无病毒后35天。
11例谁了布里斯托尔迈尔斯combinationalone，五个已清理在endof从他们的身体病毒治疗。四仍然无病毒后24周。
早期治疗，患者可能开始，如果他们不facedwith传统的C型肝炎药物毒副作用，梁霍华德说，为Leerink斯旺与公司总部位于波士顿的分析师在接受记者采访。
“如果你有一个干扰素无方案，该marketexpands相当显着，”梁文冲说。
现有的副作用干扰素疗法的副作用是oftensevere足以迫使病人请假，saidCharles戈尔，对设在日内瓦的世界肝炎病人总统advocacygroup联盟。
罗氏控股公司（玩家国度）瑞士巴塞尔，销售的品牌名称下派罗欣版本ofinterferon，而默克公司ofWhitehouse站，新泽西州的市场称为PegIntron一种形式。
默克，顶点制药公司（VRTX）和强Johnsonare有望带来adecade第一个新的丙型肝炎药物市场今年。约百分之九十的病人whotook强生公司（强生）和顶点的telaprevir治愈，剑桥，马萨诸塞州的顶点表示，两项研究lastyear。患者由于默克公司的表现同样highcure boceprevir率在去年的研究。
顶点和默克试验包括谁没有yetbeen治疗，比today'ssmaller研究这些一更易治疗组的人。相比之下，其中约30 whohadn't百分之回答了以前的治疗加上标准治疗后治愈tryingtelaprevir，研究人员说。
寻求合作伙伴默克公司正在寻求伙伴关系，以获得自己的肝炎Cdrug组合，帕特里克贝格斯特，专营权theinfectious疾病的总经理在接受采访时说。
“我们落后于别人了，”贝格斯特说。 “我们需要topartner填补了国内空白。”
施贵宝期待一个“巩固元素”ascompanies利用收购，合作和研究anddevelopment合作，以争取自己的C型肝炎drugcombinations，马尼恩说。开发协议签署后withPrinceton，新泽西州的Pharmasset公司（VRUS）1月，施贵宝是“会说话了那里几乎每家公司，”他说。
“这就像试图重新设计一辆车你rollingdown在每小时100英里的道路，因为数据comingso快，”他说。 “真是激动人心的时刻。”
要联系本故事记者：在[email protected]在法兰克福内奥米克雷奇
要联系编辑此storyhil Serafino负责在[email protected]  最后更新：上午11时46分东部，4月2日


                                       
         

limi2011321

回复 StephenW 的帖子

相关新闻：美国·健康保健。布里斯托尔迈尔斯干扰素无混合治愈肝炎C的病人的研究
由Naomi克雷奇 - 2011年4月3日上午12:48格林尼治标准​​时间0800鸣叫更多
商业ExchangeBuzz了！DiggPrint电子邮件。施贵宝公司（BMY牛）的固化在寻求治疗方法，往往不包括无毒现有药物的首次成功四丙型肝炎患者两个实验性药物的鸡尾酒。

这种组合有更高的成功率与当前配对的21人的审判标准治疗，10例治愈九，研究人员说，今天在柏林的欧洲协会肝脏的研究会议。该研究指出，为回避病毒药物的下一代，Thursz马克说，在伦敦帝国学院教授，​​肝脏病学和副主席的欧洲肝病学会的秘书。

施贵宝，总部设在纽约，是在十几家公司试图做出更好的药物组合，要么包括干扰素，​​数十年的射击，造成一半的患者流感样症状，只有作品，或者完全取代干扰素。这关系正处于市场领先地位的杰弗里斯国际有限公司由2019年的估计可能达到每年150亿美元。

“这也许是最令人兴奋的发展，今年一，”Thursz在采访中说。 “对于某些病人谁不会容忍干扰素，这是在隧道尽头的亮光。”

施贵宝计划，开始为今年监管机构批准所需的最后测试，道格拉斯马尼恩，该制药商的神经科学和病毒学研究的负责人在接受采访时说。

最难性治疗
此次试验研究了对他们来说，现有疗法没有取得成功，患者的施贵宝药物，的BMS - 790052和BMS - 650032，“最艰难到治疗人群，”马尼恩说。

十位病人得到了两种药物一起使用干扰素和利巴韦林仿制。所有无病毒标志12周治疗后已经结束。一个病人在24周时病毒的迹象，并再次在另一项跟进测试无病毒后35天。

11例谁了施贵宝的组合，仅五，从已清理在治疗结束自己的身体病毒。四仍然无病毒后24周。

早期治疗，患者可能开始，如果他们不与传统的C型肝炎的药物毒副作用面对霍华德说梁，为Leerink斯旺与公司总部位于波士顿的分析师在接受记者采访。

“如果你有一个干扰素无方案，市场的扩大相当显着，”梁文冲说。

副作用
现有的干扰素疗法的副作用往往是严重到足以迫使病人需要时间下班，查尔斯戈尔说，在日内瓦的世界肝炎病人权益团体联盟总裁。

罗氏控股公司（玩家国度）瑞士巴塞尔，销售的品牌名称下派罗欣的干扰素版本，而默克的白宫站，新泽西州市场的公司，叫做PegIntron。

默克，顶点制药公司（VRTX）和强生公司预计将在十年内第一个新的丙型肝炎药物市场今年。谁的病人约90快速反应与强生（强生）和顶点的百分之telaprevir治疗治愈，剑桥，马萨诸塞州的顶点表示，去年的两项研究。三季度，所有患者全部治愈。谁回答患者迅速默克公司的boceprevir研究显示，同样在去年，治愈率高，其中约三分之二的患者中有三分之二都被治愈。

顶点和默克试验包括谁尚未处理的，比今天的小型研究的一种更容易固化组的人。相比之下，约有30谁没有回答过去治疗的百分之们在企图telaprevir加上标准治疗痊愈，研究人员说。

寻求合作伙伴
默克公司正在寻求伙伴关系，以获得自己的C型肝炎的药物组合，帕特里克贝格斯特，专营传染病总经理在接受采访时说。

“我们落后于别人了，”贝格斯特说。 “我们需要合作，以填补缺口。”

施贵宝期待一个“综合因素”的公司利用收购，合作和研究开发合作，以争取自己的C型肝炎的药物组合，马尼恩说。在签订开发协议与普林斯顿，新泽西州的Pharmasset公司（VRUS）1月，施贵宝是“会说话了那里几乎每家公司，”他说。

“这就像试图重新设计一辆车滚下来，你每小时100英里的道路，因为数据来这么快，”他说。 “真是激动人心的时刻。”

要联系本故事记者：在[email protected]在法兰克福内奥米克雷奇

要联系编辑负责这个故事：在[email protected]菲尔Serafino
。
朗读

显示对应的拉丁字符的拼音


字典 - [url=http://www.google.cn/dictionary?source=translation&hl=zh-CN&q=Related News:U.S.  · Health Care .Bristol-Myers Interferon-Free Mixture Cures Hepatitis-C Patients in Study  By Naomi Kresge - Apr 3, 2011 12:48 AM GMT+0800 Tweet More   Business ExchangeBuzz up!DiggPrint Email .Bristol-Myers Squibb Co. (BMY)’s cocktail of two experimental drugs cured four hepatitis C patients in the first success for a therapy that excludes often-toxic existing drugs.     The combination had a higher rate of success when paired with the current standard treatment in the 21-person trial, curing nine of 10 patients, researchers said today at the Berlin meeting of the European Association for the Study of the Liver. The study points to the next generation of drugs for the evasive virus, said Mark Thursz, a professor of hepatology at Imperial College London and vice-secretary of EASL.     Bristol-Myers, based in New York, is among about a dozen companies trying to make better drug combinations that either include interferon, a decades-old shot that causes flu-like symptoms and only works in half of patients, or that replace interferon entirely. At stake is leadership in a market that Jefferies International Ltd. estimates may total $15 billion a year by 2019.     “This is perhaps one of the most exciting developments this year,” Thursz said in an interview. “For some patients who are not going to tolerate interferon, this is the light at the end of the tunnel.”     Bristol-Myers plans to begin the last trials required for regulatory approval this year, Douglas Manion, the drugmaker’s head of neuroscience and virology research, said in an interview.     Toughest-to-Treat   Today’s trial studied the Bristol-Myers drugs, BMS-790052 and BMS-650032, in patients for whom existing therapies hadn’t been successful, “the toughest-to-treat population,” Manion said.     Ten patients got the two drugs together with interferon and generic ribavirin. All showed no sign of the virus 12 weeks after the treatment was over. One patient had signs of virus at 24 weeks and was again virus-free in another follow-up test 35 days later.     Of 11 patients who took the Bristol-Myers combination alone, five had cleared the virus from their bodies at the end of treatment. Four remained virus-free after 24 weeks.     Patients may start treatment earlier if they aren’t faced with the toxic side effects of traditional hepatitis C drugs, said Howard Liang, a Boston-based analyst for Leerink Swann & Co., in an interview.     “If you have an interferon-free regimen, the market expands fairly dramatically,” Liang said.     Side Effects   Side effects of the existing interferon regimen are often severe enough to force patients to take time off work, said Charles Gore, president of the Geneva-based patient advocacy group World Hepatitis Alliance.     Roche Holding AG (ROG) of Basel, Switzerland, sells a version of interferon under the brand name Pegasys, while Merck & Co. of Whitehouse Station, New Jersey markets a form called PegIntron.     Merck, Vertex Pharmaceuticals Inc. (VRTX) and Johnson & Johnson are expected to bring the first new hepatitis C drugs in a decade to the market this year. About 90 percent of patients who responded quickly to treatment with Johnson & Johnson (JNJ) and Vertex’s telaprevir were cured, Cambridge, Massachusetts-based Vertex said in two studies last year. Three-quarters of all patients were cured. Patients who responded quickly to Merck’s boceprevir showed similarly high cure rates in studies last year, with about two-thirds of all patients being cured.     The Vertex and Merck trials included people who hadn’t yet been treated, an easier-to-cure group than those in today’s smaller study. By comparison, about 30 percent of those who hadn’t responded to previous treatment were cured after trying telaprevir plus standard therapy, researchers said.     Seeking Partners   Merck is seeking partnerships to gain its own hepatitis C drug combinations, Patrick Bergstedt, general manager of the infectious diseases franchise, said in an interview.     “We’re b]查看字典详细内容[/url]

wa3006

StephenW 老兄：你尊重原文，但我们看不懂啊？可以可以麻烦你再发原文的同时简单翻译一下，免得我们去猜，网上的英译汉软件不能完全翻译，谢谢啊！

StephenW

wa3006 发表于 2011-4-4 22:46
StephenW 老兄：你尊重原文，但我们看不懂啊？可以可以麻烦你再发原文的同时简单翻译一下，免得我们去猜， ...

很抱歉, 我是海外华人，我写的中文不好, 只能靠软件翻译.请良好英语的读者帮助.

简单翻译: Bristol-Myers的新药物可以治愈丙肝.

我随心动

“two experimental drugs cured four hepatitis C patients in thefirst success for a therapy that excludes often-toxic existingdrugs. ”
我来简单翻译第一句，两种试验药物治愈了4名丙肝患者，不包含通常有毒性的现用药物。
后面没细看，只看这一句就很振奋人心啦，可以不受干扰折磨是好事情。

StephenW

我随心动 发表于 2011-4-5 09:06
“two experimental drugs cured four hepatitis C patients in thefirst success for a therapy that excl ...

谢谢, 好消息,一句就足够.

wa3006

我也坚信丙肝很快会能够轻松治愈，在新药还没有大面积推广以前，我一定要挺住，呵呵，谢谢StephenW 带来的好消息！